Try Alerts Free   |   Login
Health Care › Surgical And Medical Instruments And Apparatus

ATEC Price Correlated With Financials For Alphatec Holdings

Free historical financial statements for Alphatec Holdings Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 42 quarters since 2012. Compare with ATEC stock chart to see long term trends.

ATEC Stock Compared to Quarterly

ATEC Income Statement

Revenue, Net:89839000
Revenue Per Share:0.8551
Cost of Goods & Services Sold:30323000
Gross Profit:59516000
Selling, General & Admin Expense:75954000
Research & Development Expense:12111000
Total Operating Expenses:94486000
Operating Income:-36870000
Income Taxes:129000
Net Income:-36999000
Earnings Per Share, Basic:-0.35
Shares Outstanding, Basic Avg:105058324

ATEC Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:10812000
Change in Accounts Receiveable:7878000
Net Cash from Operations:-14690000
Net Cash from Operations Per Share:-0.1398
Net Cash from Financing Activities:29444000
Property, Plant & Equipment Purchases:9646000
Net Cash from Investing Activities:-15628000
Net Change in Cash & Equivalents:-1358000

ATEC Balance Sheet

Cash and Cash Equivalents:106112000
Accounts Receivable, Net:50723000
Inventories:102159000
Total Current Assets:268712000
Property, Plant & Equipment, Net:98908000
Total Assets:516283000
Accounts Payable:33374000
Current Portion of Long-Term Debt:13550000
Total Short-Term Liabilities:125487000
Long Term Debt, Non-Current Portion:348324000

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock Inc.
4,944,209 sh
-5,190 sh
0%
$43,213
$10,844
Vanguard Group Inc
3,502,419 sh
69,652 sh
2%
$30,612
$8,161
First Light Asset Management, LLC
2,974,658 sh
256,538 sh
9%
$25,999
-$5,259
Deerfield Management Company, L.P. (Series C)
2,532,792 sh
112,245 sh
5%
$22,137
$6,307
Armistice Capital, LLC
2,436,000 sh
-488,000 sh
-17%
$21,291
$2,168
Janus Henderson Group Plc
1,935,609 sh
-125,878 sh
-6%
$16,916
$3,433
Next Century Growth Investors LLC
1,916,519 sh
243,684 sh
15%
$16,750
$5,810
State Street Corp
1,753,175 sh
-261,600 sh
-13%
$15,323
$2,146
Avidity Partners Management Lp
1,715,000 sh
 
$14,989
Cerity Partners LLC
1,595,229 sh
 
$13,942
JPMorgan Chase & Co
1,587,766 sh
1,392,398 sh
713%
$13,877
$12,599
King Luther Capital Management Corp
1,386,669 sh
239,985 sh
21%
$12,119
$4,620
Millennium Management LLC
1,357,194 sh
303,735 sh
29%
$11,862
$4,972
Driehaus Capital Management LLC
1,341,205 sh
-34,296 sh
-2%
$11,722
$2,726
Geode Capital Management, LLC
1,324,484 sh
24,519 sh
2%
$11,575
$3,074
Royal Bank Of Canada
1,224,894 sh
-53,783 sh
-4%
$10,705
$2,344
Deutsche Bank Ag\
1,182,957 sh
7,465 sh
1%
$10,338
$2,651
Point72 Asset Management, L.P.
915,200 sh
203,900 sh
29%
$7,999
$3,347
New York State Common Retirement Fund
902,793 sh
7,940 sh
1%
$7,890
$2,038
Citadel Advisors LLC
719,125 sh
706,525 sh
5607%
$6,285
$6,203
COMPANY PROFILE
1. The Company and Basis of Presentation
The Company
Alphatec Holdings, Inc. (the “Company”), through its wholly owned subsidiaries, Alphatec Spine, Inc. (“Alphatec Spine”), SafeOp Surgical, Inc. (“SafeOp”), and EOS imaging S.A. (“EOS”), is a medical technology company that designs, develops, and markets technology for the treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The Company markets its products in the U.S. and internationally via a network of independent distributors and direct sales representatives.
Basis of Presentation
The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") and include the accounts of the Company and its wholly owned subsidiaries. The Company translates the financial statements of its foreign subsidiaries using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. All intercompany balances and transactions have been eliminated in consolidation. The Company operates in one reportable business segment.
Reclassification
Certain amounts in the consolidated financial statements for the year ended December 31, 2020 have been reclassified to conform to the current year’s presentation. These reclassifications were immaterial and have no impact on previously reported results of operations or accumulated deficit.
Recent Developments
0.75% Senior Convertible Notes due 2026
In August 2021, the Company issued $316.3 million principal amount of unsecured senior convertible notes (the “2026 Notes”) with a stated interest rate of 0.75% and a maturity date of August 1, 2026. The net proceeds from the sale of the 2026 Notes were approximately $306.2 million after deducting the offering expenses. See Note 6 for additional information on the 2026 Notes.
Acquisition of EOS
On May 13, 2021, the Company acquired a controlling interest in EOS, pursuant to the Tender Offer Agreement (the “Tender Offer Agreement”) it entered into on December 16, 2020, and in June 2021 purchased the remaining issued and outstanding ordinary shares for a 100% interest in EOS. EOS, which now operates as a wholly owned subsidiary of the Company, is a global medical device company that designs, develops and markets innovative, low dose 2D/3D full body and weight-bearing imaging, rapid 3D modeling of EOS patient X-ray images, web-based patient-specific surgical planning, and integration of surgical plan into the operating room that collectively bridge the entire spectrum of care from imaging to post-operative assessment capabilities for orthopedic surgery. See Note 3 for additional information on the business combination.
COVID-19 Pandemic
In 2020, a novel strain of Coronavirus, which causes COVID-19, was identified and declared by the World Health Organization to be a pandemic. The virus causing COVID-19 has since rapidly spread across the globe to all countries, including to the United States. To slow the spread of COVID-19, governments have implemented measures, which include the mandatory closure of businesses, and restrictions on travel. In addition, many government agencies in conjunction with hospitals and healthcare systems have, to varying degrees, deferred or suspended elective surgical procedures. While certain spine surgeries are deemed essential and certain surgeries cannot be delayed, the Company has seen and may continue to see a reduction in procedural volumes as hospital systems and/or patients elect to defer spine surgery procedures and hospital systems experience staffing shortages.
The cumulative effect of these disruptions had an impact on the Company’s business during the years ended December 31, 2021 and 2020. The COVID-19 pandemic continues to evolve and its full impact on the Company’s business will depend on several factors that are uncertain and unpredictable, including, th

Data imported from Alphatec Holdings Inc. SEC filings. Check original filings before making any investment decision.